Rituximab for Treatment of Membranoproliferative Glomerulonephritis and C3 Glomerulopathies

Table 2

Reports on rituximab treatment in C3 glomerulopathy and dense-deposit disease. RTX: rituximab, C3GN: C3 glomerulopathy, DDD: dense-deposit disease, MMF: mycophenolate mofetil, RAS: renin angiotensin system, C3Nef: C3 nephritic factor, TCC: terminal complement complex, CFH: complement factor H, CFI: complement factor I, MCP: membrane cofactor protein, and CR and PR: complete and partial remission (as defined by the authors).

Authors	Diagnosis	Follow-up	Other therapy	RTX protocol	Laboratory parameters	Outcome
Daina et al. [41]	DDD	5 months for RTX; 48 months for eculizumab	Steroids; Eculizumab; RAS blockade	mg/m^2	C3Nef positive; C3 < 10%; TCC high; Genetics (CFH variants V62 and H402)	No effect of RTX on renal function or proteinuria; PR with eculizumab
Rousset-Rouvière et al. [42]	DDD	21 months	Steroids; MMF; Eculizumab; RAS blockade	mg/m^2	C3 < 0.04 g/L; C4 normal; C3Nef positive; Genetics: normal (CFH, CFI, MCP); Anti-CFH negative	Acute renal failure after RTX; CR with eculizumab
Giaime et al. [40]	DDD	30 months	RAS blockade	mg weekly; repeated after 18 months	Creatinine 235 μmol/L; Proteinuria 6 g/day; C3 0.12 g/L (low); C4 normal; C3Nef positive	Creatinine 200 µmol/L; Proteinuria < 0.5 g/L; C3 remained low; C3Nef remained positive
Payette et al. [43]	C3GN	72 months	Steroids; MMF; Eculizumab	mg/m^2	Proteinuria 1–5.3 g/day; C3Nef positive; CFI mutation (I398L); anti-CFH positive; low C3	No effect of RTX on proteinuria; PR with eculizumab; Normal renal function